Background {#Sec1}
==========

Pharmaceutical care is the direct, responsible provision of medication-related care for the purpose of achieving definite outcomes \[[@CR1]\]. Though identifying, solving and preventing medication problems, finding out prescription errors and medication-related injuries by clinical pharmacists, incidence of adverse events and rehospitalization rates could be reduced. Patient adherence of the treatment could be significantly improved and possible harm due to medication problems had been reduced after patients received their medication instructions \[[@CR2]\]. Medication education and treatment advice from clinical pharmacists could also shorten hospital stay \[[@CR3]\].

Studies have shown that hospital pharmaceutical care had great value in clinical and economic aspects. In a diabetes management team, participation of clinical pharmacists led to the reduction of hemoglobin, cholesterol and blood pressure in patients as well as the significantly lower cost of medication for each patient \[[@CR4]\]. A study showed the implementation of antifungal practice guidelines by a clinical pharmacist, member of an ICU team, resulted in a 50% cost reduction in expenditure on antifungal agents \[[@CR5]\]. However, whether there was a direct connection between this service and the improvement of patient health had been discussed. Meanwhile, costs of running pharmacy service and its economic benefits were at issue in some countries. These worries impeded the development of hospital clinical pharmacy and its universal implement. Among factors mentioned above, lack of strong, direct evidence is one potential barrier.

Although many studies noticed the clinical and economic outcomes of hospital pharmaceutical care, few systematically demonstrated and validated the effectiveness of hospital pharmaceutical care. Due to flaws in experimental design and source of literature, non-randomized controlled trials, low methodological quality of included studies or unconvincing experimental data, evidence on effectiveness and validity are still insufficient. Therefore, it is necessary to explore its clinical and economic outcomes from the scope of a more general perspective. In the present study, a systematic review and meta-analysis for pooling statistical power was conducted to systematically evaluate the clinical and economic outcomes of hospital pharmaceutical care.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

Two researchers searched for relevant articles published in databases including Pubmed by Medline, Embase, Cochrane and CINAH (January 1992 to October 2019). Key words included pharmaceutical service/care/intervention, pharmacy service/care/intervention, pharmacist service/care/intervention and clinical outcomes, evaluations, effects, assessment, outcomes, practice. And it is supplemented by such truncated words as "service \*", "analysis \*", "evaluate \*", "effect \*", "Pharmac \*", "intervene \*", "practi \*", "impact \*". The retained researches were supplemented by access to monographs, reviews, references to published articles, and recently published Chinese and English journal articles. Two reviewers independently searched and discussed and resolved discrepancies.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Studies would be included when interventions or participation of clinical pharmacists were considered with detailed descriptions of services they provided. The research setting should be conducted in hospitals. The research conducted should involve intervention groups and control groups who received routine care or non-interventions from clinical pharmacists. The clinical outcomes or economic outcomes of the interventions should be evaluated. Studies only abstracts available were excluded.

Data extraction and validity assessment {#Sec5}
---------------------------------------

The data extraction was independently carried out by the researchers using a standard electronic form Microsoft Excel 2016 and the extracted data was checked by two researchers. According to the Cochrane systematic review guidelines, combined with the aim of this study and quality assessment requirements, extracted data in the feature tables included: For numbered lists Literature characteristics (Table [1](#Tab1){ref-type="table"}): author, publication year, country, sample source, interventions, primary outcomes and effects.Methodological quality assessment table: correct randomization method, hidden allocation scheme, blindness method, whether there is bias due to missing data.Table 1Literature CharacteristicsNO.Author (year) countrySample descriptionPharmacist interventionsPrimary outcomesEffect1Bill et al \[[@CR6]\] (1992) USFrom 1984 to 1987, patients admitted to the hospitals, 432 admissions on four general medicine services over 12 monthsProvide a brief guidebook, a booklet on cost strategies and common expenses, detailed temporary bills, and information on the number of days hospitalized and the usual hospitalization costsHospitalization days, diagnosis-related group adjustment costs, direct standardization chargesPositive2Maryanne \[[@CR7]\] (1992) USNot reportedChange dosage and content of prescriptions; discontinue use of prescriptionsavoided costsPositive3Carter et al \[[@CR8]\] (1997) USAdult patients with primary hypertension in any ethnic group in a Christian medical clinic, 25 in the intervention group and 26 in the control groupVisit patients every 3--5 weeks and get drug supplement; measure blood pressure and pulse; inquire about adverse drug reactions and improve adherence to treatment at each follow-up; write a complete progress record; evaluate the patient's current medical treatment and understanding of lifestyle changes; record all patient data and send a copy to the patient's physicians for review; pharmacists and physicians involved at that time contacted and provide services for patients who needed to change medications; standardize patient education, distribute brochures, visual materials, and verbal instructionsBlood pressure, visits, medication costsPositive4GL et al \[[@CR9]\] (1997) USPatients who received parenteral antibiotics from January to March 1994 at the Portland Hospital in the US, 141 in the intervention group and 111 in the control groupProvide patient-specific, antibiotic-related advice to the attending physician (by a team of infectious disease researchers and clinical pharmacists)Reuse of antibiotics, mortality, per capita antibiotic costsNo effect5Gums et al \[[@CR10]\] (1999) USIn the adult patient with uncontrolled dyslipidemia defined by the 2009 Canadian Dyslipidemia Guidelines, 43 were in the intervention group and 44 in the control group.Determine the best intravenous antibiotics; advise on antibiotic treatment and monitoringHospitalization time, average hospitalization days, hospitalization costs, patient mortalityPositive6Dager et al \[[@CR11]\] (2000) USA 400-bed teaching hospital, patients older than 18 years old, who received warfarin for the first time, the 60 patients hospitalized in 1992 were the control group, and 60 patients hospitalized in 1995 were intervention groups.Review the patient's medication history; provide written consultations daily on the medical charts of patients with warfarin dosing recommendationsHospitalization days, average INR at the time of discharge from the INRPositive7Canales et al \[[@CR12]\] (2001) USFrom May to December 1997, any psychiatric patient admitted to the Austin National Hospital with acute psychotic symptoms, 45 in the intervention group and 48 in the control groupParticipate in treatment group meetings; perform baseline assessments and weekly observations; provide medication recommendations; obtain medication history; review drug administration daily records; monitor adverse drug reactions; conduct medication education classes; consult patients before they leave the hospitalAverage medical treatment cost per patient during hospitalizationPositive8Brook et al \[[@CR13]\] (2003) NetherlandsFrom April 2000 to April 2001, patients who went to pharmacies to purchase antidepressant drugs, 64 in the intervention group and 71 in the control groupIntroduce drugs and drug efficacy to patients and discuss ways of drug use; provide videos related to pharmaceutical education and patient counselsThe number of positive drug attitudesPositive9Bolas et al \[[@CR14]\] (2004) UKThe hospitalized patients in the Antrim district hospital were 81 in the intervention group and 81 in the control groupPrepare accurate drug records after full review of current drug use; drug counseling; provide medication record forms to inform patients on how to take medication; provide medications detailing changes in drug treatment; release letter (general practitioner faxed to patient on the day of discharge community pharmacist); provide helpline for medicinesAverage mismatch rate between discharge prescription and household medication, average error rate of drug treatment knowledgePositive10Carter et al \[[@CR15]\] (2009) USMen and women aged over 21 in 6 clinics diagnosed as essential hypertension, taking 0 to 3 compression medicines, 192 intervention groups and 210 control groupsmake drug therapy recommendations to physicians based on national guidelinesBlood pressure, blood pressure control ratePositive11Wong et al \[[@CR16]\] (2010) SingaporeFrom 2006 to 2007, patients in the general medical and surgical departments of a 1200-bed nursing teaching hospital in Singapore who initially started taking warfarin for deep vein thrombosis, pulmonary embolism or atrial fibrillation, intervention group 144 and control group 26Support the commencement and titration of warfarin anticoagulant services; provide written counseling and discuss the case with the doctor; recommend daily warfarin's dose; check and monitor patients' International Normalization Ratio until they are ready for discharge; recommend discharge doses and appointment dates for anticoagulation clinicsHospitalization days, international standardized ratio, average number of days dischargedPositive12Hammad et al \[[@CR17]\] (2011) JordanFrom March to November 2009, patient enrolled in the family medical clinic of Jordan University Hospital, 110 in the intervention group and 89 in the control groupProvide a 30-min consultation before meeting with a physicianTriglycerides, high-density lipoprotein cholesterol, blood sugar, Blood pressurePositive13Shen et al \[[@CR18]\] (2011) ChinaBetween July 2009 and April 2010, inpatients in two separate respiratory wards at three teaching hospitals, 178 in the control group and 176 in the intervention groupcommunicate with physicians; make recommendations on treatment optionsHospitalization costs, antibiotic costs, hospitalization daysPositive14Mousavi et al \[[@CR19]\] (2012) IranPatients who had at least one significant risk factor or at least two related risk factors in the kidney ward of the Iranian Khomeini Hospital Complex for 6 months, 375 in the intervention group and 236 in the control groupescort physicians in the ward and gives suggestionsAppropriate and inappropriate stress ulcer prophylaxis management per patient costPositive15Shah et al \[[@CR20]\] (2012) USBetween 2010 and 2011, diabetes patients over 18 years old in a public hospital and health care system, 31 in the intervention group and 21 in the control groupConsult on routine care and post-discharge diabetes drug dosage, side effects and clinical benefits; concurrent diabetes mellitus symptoms, hypoglycemia, healthy eating, exercise and reduced use guidelines emotional education; follow-up after dischargeCholesterol, lipoprotein, Blood pressure, glycated hemoglobinPositive16Zhang et al \[[@CR3]\] (2012) ChinaThe pediatric patients with neurological diseases, respiratory diseases or digestive diseases in the Second Hospital of HuaXi, Chengdu, China, 76 in the intervention group and 74 in the control groupAnswer questions from doctors and nurses; provide treatment advice; prevent medication errorsHospitalization days, medical cost per patient, readmission rateMixed17Cies, Varlotta \[[@CR21]\] (2013) USFrom January 2007 to August 2008 in St. Christopher's Children's Hospital, 29 in the intervention group and 22 in the control groupSpecialized clinical pharmacists monitor and adjust drug dosing; monitor initial and subsequent tobramycin levelsTotal cost, hospitalization cost, dose adjustment cost, average hospitalization daysPositive18Ho et al \[[@CR22]\] (2013) UKFrom January 1, 2004 to March 31, 2007, patients admitted to the Royal Hospital of Colombia had 333 interventions and 1228 patients in the control groupThe presence or absence of one or more clinical pharmacy notes recorded in the inpatient record during the ICU admissionComplete cohort mortalityPositive19Chilipko, Norwood \[[@CR23]\] (2014) USFrom January 1, 2009 to January 1, 2011 in a community teaching hospital, patients are over 18 years old and receive warfarin for at least 3 days, 125 in the intervention group and 108 in the control groupProvide anticoagulation management services for warfarin; daily monitor warfarin dosageIn-hospital average treatment time, hospitalization period average number of days for achieving INR goals, total incidence of bleeding, average albuminMixed20Grimes et al \[[@CR24]\] (2014) UKBetween July 2010 and May 2011 Adult patients at the Tallaght Hospital in Dublin, Ireland, 112 in the intervention group and 121 in the control groupMedication reconciliation and prescription exams; understand the inpatient history of medicationErrors in medication, changes in cumulative drug adaptability index before admission to hospital and after dischargePositive21Joost et al \[[@CR25]\] (2014) GermanyFrom August 2008 to July 2010 at the Erlangen University Hospital, patients who were able to visit repeatedly for outpatients with kidney disease and hypertension, 35 in the intervention group and 39 in the control groupProvide additional inpatient and outpatient pharmaceutical care; counsel by a specialized clinical pharmacistPercentage of days of correct dosage, pc adhesion ratePositive22Tan et al \[[@CR26]\] (2014) AustraliaFrom December 2011 to January 2013, in two general practice clinics in Melbourne, Australia, 62 patients with one or more risk factors for medication-related problems, sample size 62 peopleProvide face-to-face consultations; interview in private clinics for about 30--60 min; resolve issues related to identifying drugs at homePatient's rate of adherence to their medication, health scorePositive23Vervacke, Lorent, Motte \[[@CR27]\] (2014) BelgianFrom September 2009 to March 2012, in a Belgian urban academic hospital who aged 75 or older with a history of venous thromboembolism or cancer, 336 before the intervention, 431 after the interventionProvide education for specific physicians and nurses; disseminate teaching tools to summarize guidelines and reminders for venous thromboembolism preventionNumber of patients at risk of venous thromboembolismPositive24Xin et al \[[@CR4]\] (2014) ChinaFrom January to December 2013, in Zhejiang Province Tongde Hospital who is less than 18 years old, diagnosed as type 2 diabetes, 420 before the intervention, 429 after the interventionA full-time experienced pharmacist served in the teamHemoglobin, lipoproteins, triglycerides, Blood pressure, hospitalization days, medication costsPositive25Zhang et al \[[@CR28]\] (2014) ChinaFrom 2011 to 2012, inpatients undergoing cleansing or decontamination operations in the Department of Urology, 174 before intervention and 196 after interventionMonitor drug information and make medical records in real time through the hospital information system; establish standards for the administration of preventive antibiotic prescriptions through hospital managementDrug costs, antibiotic prevention delay daysPositive26Campo, Roberts, Cooter \[[@CR29]\] (2015) AustraliaUniversity of South Australia's Higher Education Hospital Flinders Medical Center admitted to the respiratory ward in July 2010, 31 patients in the intervention group and 30 in the control groupMeasure 4 whole-day glycemic profiles 24 h per phase (Non-diabetic patients with chronic obstructive pulmonary disease); daily test 4 whole-day glycemic profiles (patients with chronic obstructive pulmonary disease); blood glucose levels are at 700 h, 1200 h, 1700 h (before meals) and 2100 h for routine monitoringAchieve daily minimum blood glucose monitoring level, cross-time blood glucose level testPositive27Delpeuch et al \[[@CR30]\] (2015) FrenchDepartment of Hematology/Oncology, Affiliated Hospital of Medical School, Patient with solid tumor (excluding lung cancer), sample size 552Comprehensive drug review (chemotherapy, supportive care and outpatient treatment)Drug related issuesMixed28Obarcanin et al \[[@CR31]\] (2015) Yugoslavia and GermanyTwo paediatric clinics in the Krefeld region of Germany and Sarajevo, Bosnia and Herzegovina, 39 in the intervention group and 26 in the control groupProvide access to pharmaceutical services monthly and record clinical data during visits; patients in the intervention group measured at least 4 times daily blood glucose; assess drug-related needs and identify problems; develop an individualized pharmaceutical care plan for each patient; pharmacists discuss the drug care plan with physiciansGlycated hemoglobinPositive29Wolf et al \[[@CR2]\] (2015) UKFrom September 2012 to December 2013, 269 mental patients were sent to the psychiatric department, 131 in the intervention group and 134 in the control groupProvide detailed medication reconciliation at admission and medication reviews at discharge and 3 months after discharge; two clinical pharmacists follow each week during hospitalizationChange in drug fitness index, number of medication-related issuesPositive30Burnett et al \[[@CR32]\] (2016) USAll patients who received heparin-induced thrombocytopenia per-intervention (10/1/2009--9/ 30/2010) and post-intervention (10/1/2010--9/30/2011) had 167 patients before the intervention, 104 people after the interventionThe pharmacy-driven 4 T score (4 T pretest probability score) interventionCalculated 4 T score, number of patients with major bleeding, number of patients with thrombotic events, average cost per patientPositive31Gallagher et al \[[@CR33]\] (2016) UKFrom June 2011 to June 2012, hospitalized patients in an 810-bed teaching hospital in Ireland, 361 people in the intervention groups and 376 people in the control groupProvide medication reconciliation, deployment of clinical decision support software; formulation of a pharmaceutical health planTotal cost, adverse drug reactionsMixed32Khalil V et al \[[@CR34]\] (2016) AustraliaInpatients in general hospitals in a hospital in Australia, 56 in the intervention group and 54 in the control groupPharmacist medication guidanceMedication errors, the severity of prescribing errorsPositive33Phatak et al \[[@CR35]\] (2016) USFrom November 2012 to June 2013, patients discharged from the 894-bed academic medical center or western memorial hospital of the Northwest Memorial Hospital in Chicago, Illinois, 137 in the intervention group and 141 in the control groupFace-to-face medication reconciliation; a patient-specific pharmaceutical care plan; discharge counseling; post discharge phones call on days 3, 14, and 30 to provide education and assess study endpointsHigh-risk average, number of days admitted to hospital/emergency, drug-related readmissions, general hospital admissionsPositive34Watersl et al \[[@CR36]\] (2017) USA hospital in the US had been discharged from the emergency department and had been discharged, and was later found to be a positive bacterial pathogen in the blood culture. 138 were in the intervention group and 107 in the control groupProvide advice on proper antibiotic selection, dosage, route, and duration; evaluate the efficacy of excretion antibiotics and intervene when pathogen-antibiotic mismatches are found; reduce workload of physicians' in emergency departments; improve antimicrobial management experience in the culture processProportion of patients receiving appropriate antibiotic treatment, rate of admission or readmission within 90 days, the number of 90-day cases of illnessPositive35Sloeserwij et al \[[@CR37]\] (2019) NetherlandsFrom January 2013 to May 2015, 11,928 high-risk patients were included10 specially trained non-dispensing pharmacists took integral responsibility for the pharmaceutical care. They provide a wide range of medication management services at the patient level (e.g. clinical drug review) and the level of practice (e.g. quality improvement projects).the number of medication-related hospitalisationsPossitive36Schumacher et al \[[@CR38]\] (2018) USFrom November 2009 toAugust 2010, Clinical pharmacists visited and intervened 111 patients with chronic heart failure.Clinical pharmacists improve hospitalization rates and 30-day readmission rates for heart failure through more frequent follow-up and improved access to care. Clinical Spaces have been established for clinical pharmacists including patient visit rooms and independent provider schedules. But the need for other chronic comorbidity quickly became apparent, requiring expanded services and the role of clinical pharmacists within months of the establishment of the practice.readmission ratesPossitive37Korcegez et al \[[@CR39]\] (2017) Northern CyprusFrom October 2013 to July 2015,152 patients were treated in the diabetes clinic of a public hospital in gazimagus, northern Cyprus. The patients were divided into two groups: intervention group (75 cases) and usual care group (77 cases).Each patient scheduled a meeting with the study clinical pharmacist on the same day as the doctor's appointment. The pharmacist interviewed the patient in an independent office next to the doctor's office. The intervention group conducted 5 consecutive visits with a pharmacist every 3 months and reviewed the medication and treatment plan.change in A1cPossitive38Domingues et al \[[@CR40]\] (2017) SpainFrom April 2013 to November 2014, the study population included 42 patients receiving treatment from the third hospital pharmacy outpatient department and receiving antiretroviral therapy.Drug treatment was followed up using the dader method. Interviews were conducted every 2 months. During each interview, the patient's medication, health problems, and modifiable cardiovascular risk factors were assessed. Direct drug care interventions to patients when lifestyle changes or improved treatment compliance are required. If treatment needs to be evaluated, the doctor receives a written report.changes in cardiovascular riskPossitive39Ospina et al \[[@CR41]\] (2017) ColombiaFrom November 2011to June 2014, 92 patients were randomly divided into intervention group (43) and control group (49).The pharmacist calls every week until the end of the study. During these calls, the pharmacist did the following: (a) conducting clinical assessments, assessing changes in mood, behavior, regular eating and sleep patterns, language and thinking; (b) emphasizing the importance of patient education and the identification and management of prodromal symptoms; (c) to explain the correct use of bipolar drugs; (d) promoting treatment compliance; and (e) promoting healthy eating and lifestyle habits.hospitalizations and emergency service consultations, unscheduled outpatient visits, clinical evaluation of depression and maniaMixed40Javaid et al \[[@CR42]\] (2019) PakistanFrom August 2016to June 2017, there were 52 and 83 patients in the control and intervention arm, respectivelyPharmacological interventions involve working with doctors to identify drug-related issues, drug interactions, dose, frequency changes, and treatment transitions, whereas non- pharmacological interventions involve diet, lifestyle, and behavioral counseling.glycemic (HbA1c), lipid controls.Possitive41Shao et al \[[@CR43]\] (2017) ChinaAfter strict screening, 120 patients were randomly divided into two groups. And one hundred ninety-nine patients completed the studyInterviews included face-to-face interviews (once every other month) and telephone follow-up (every month) until the end of the study. During the interview, the pharmacist discussed about their medication compliance, self-monitoring of blood sugar control, and exercise; explained side effects and possible drug interactions; and reminded them to see the doctor next time.FBG, HbA1c, TC, the target attainment rates of HbA1c, BPPossitive42Juanes et al \[[@CR44]\] (2018) USFrom January 2012 and February 2013, patients were allocated in a 1:1 ratio of potential drug-related problems (intervention group) or administered as standard care (control group).review the following aspects of the patient's medication: (a) the indications of each drug are related to the patient's condition; (b) the suitability, dose, plan, and treatment time of each drug are related to the patient's age and / or clinical status (renal or liver function). In addition, therapeutic drug monitoring was carried out for drugs with narrow treatment range.. Follow up. Assess the effectiveness and safety of treatment based on standard clinical practice and objective patient data from clinical records.drug-related negative outcomesPossitive

When comparing the main outcomes of experimental groups and control groups, *p* \< 0.05 was viewed statistically significant. When the primary outcomes of the experimental group were significantly better than the control group, it was marked as "positive"; and when there were no significant difference between the two groups, it was viewed as "no effect". For studies evaluating multiple primary outcomes and not positive outcomes, those who presented at least one major positive outcome were considered as "mixed".

Meta-analysis {#Sec6}
-------------

In this study, Stata 15 was used for meta-analysis. After calculating the number of studies with common outcomes, systolic blood pressure (SBP), diastolic blood pressure (DBP), medical cost, and hospitalization days remained for meta-analysis. The standard mean difference (SMD) was used as the effect quantity, the significance level (or) of the combined effect quantity test was 0.05, the significance level of the heterogeneity test was 0.1, and the overall estimate was expressed by the point estimate and 95% confidence interval (95% CI). If there is significant heterogeneity such as research subjects and interventions in the studies used to perform meta-analysis, these studies would not be directly combined. Statistical consistency was assessed using chi-square tests and I^2^ statistics for heterogeneity. If *p* \> 0.1, no heterogeneity was considered. If *p* \< 0.1, heterogeneity between studies was considered.

Results {#Sec7}
=======

Search and study selection {#Sec8}
--------------------------

Three thousand two hundred thirty-eight documents were obtained through database searching with a manual search of 61 added references related to empirical researches on hospital pharmaceutical care. After removing duplicate articles, 2284 articles remained. Through reviewing titles and abstracts, 1634 irrelevant articles were excluded. After reading full texts, 577 articles inconsistent with this study were excluded. And 73 studies deemed suitable were assessed and excluded after screening (Fig. [1](#Fig1){ref-type="fig"}). Finally, 42 studies were included for the meta-analysis. Fig. 1Selection of study

Summary of included studies {#Sec9}
---------------------------

Relevant studies were published mainly in Europe countries and America. There were 16 studies from the United States and 5 studies from the United Kingdom; 5 studies from China; 3 studies from Australia; 2 studies from Germany and Netherlands; other studies from Singapore, Iran, France, Jordan, etc. Diseases interfered included hypertension, diabetes, nephropathy, etc. Since 2010, researches on effectiveness of hospital pharmaceutical care have greatly increased, especially in 2014. And diseases concerned shifted from traditional diseases with high-incidence to epidemic, chronic diseases. For observing changes after receiving pharmaceutical care from clinical pharmacists, most samples were inpatients. In terms of interventions, most pharmacist interventions were diverse. Patient education programs, physician advice, disease state monitor and management were referred to in most researches provided. As for effects of hospital pharmaceutical care, among the 42 articles included, 36 studies had positive effects, 5 studies had mixed effects, and one study had no effect.

Methodological quality of studies {#Sec10}
---------------------------------

Of the 42 studies included, 17 studies belonged to high quality studies with scores of 3--4, and the remaining 23 studies were low-quality studies (1--2 score). Among 42 studies, there were 20 randomized controlled trials, 11 non-randomized controlled trials, and 11 cohort studies. Seventeen studies reported loss of withdrawal and 20 studies reported sample baselines, taking into account the effects of randomization, blinding, and allocation concealment on selection bias, implementation bias, and measurement bias.

Meta-analysis {#Sec11}
-------------

### Meta-analysis of hospital pharmaceutical care on SBP {#Sec12}

A total of nine studies included blood pressure data, one of which missed standard deviation of the sample, and one experiment had an uneven baseline. Results of the meta-analysis of SBP by random effects model are shown in Table [2](#Tab2){ref-type="table"}, Fig. [2](#Fig2){ref-type="fig"}. The results of SBP heterogeneity test were significant (I^2^ = 82.1%, *p* = 0.000 \< 0.1). The test results showed *p* = 0.000 \< 0.05, indicating that hospital pharmaceutical care had a significant effect on the reduction of SBP, compared to usual care. The mean difference of SBP between the intervention groups and control groups was − 0.573 (95% CI, − 0.851 to − 0.295). Table 2Results of Meta-analysis of systolic blood pressureStudy\| SMD\[95% Conf. Interval\]% WeightCarter (1997) \[[@CR8]\]\| -0.173− 0.7230.37710.66Carter (2009) \[[@CR15]\]\| -0.596−0.796− 0.39616.73Schumacher (2018)\| -0.696−0.927−0.46516.26Korcegez (2017)\| -0.574−0.899− 0.25014.65Domingues (2017) \[[@CR40]\]\| -0.301−0.7320.12912.73Javaid (2019) \[[@CR42]\]\| -1.456−1.844−1.06713.49Shao (2017)\| -0.148−0.4260.13115.47D + L pooled RR\| -0.573−0.851−0.295100.00Heterogeneity chi-squared = 33.52 (d.f. = 6) *p* = 0.000.I-squared (variation in SMD attributable to heterogeneity) =82.1%.Estimate of between-study variance Tau-squared = 0.1096.Test of SMD = 0: z = 4.04 *p* = 0.000.The significance level of the combined effect quantity test: 0.05.The significance level of the heterogeneity test: 0.1.Heterogeneity test: *p* \> 0.1, no heterogeneity was considered; *p* \< 0.1, heterogeneity was considered.Fig. 2Forest figure of systolic blood pressure

### Meta-analysis of hospital pharmaceutical care on DBP {#Sec13}

A total of nine studies included blood pressure data, one of which missed the standard deviation of the sample, and one experiment had an uneven baseline. Results of the meta-analysis of DBP by random effects model are shown as Table [3](#Tab3){ref-type="table"}, Fig. [3](#Fig3){ref-type="fig"}. Heterogeneity test results on DBP were significant (I^2^ = 67.3%, *p* = 0.005 \< 0.1). The test results showed that *p* = 0.002 \< 0.05. It was shown that compared with usual care, hospital pharmaceutical care had significant effect on DBP. The average DBP difference between intervention group and control group was − 0.329 (95% CI, − 0.532 to − 0.125). Table 3Results of Meta-analysis of diastolic blood pressureStudy\| SMD\[95% Conf. Interval\]% WeightCarter (1997) \[[@CR8]\]\| 0.110−0.4390.6608.55Carter (2009) \[[@CR15]\]\| -0.108−0.3040.08718.74Schumacher (2018)\| -0.654−0.884−0.42417.58Korcegez (2017)\| -0.584−0.908−0.25914.37Domingues (2017) \[[@CR40]\]\| -0.285−0.7150.14411.27Javaid (2019) \[[@CR42]\]\| -0.402−0.752−0.05213.57Shao (2017)\| -0.203−0.4820.07515.91D + L pooled SMD\| -0.329−0.532−0.125100.00Heterogeneity chi-squared =18.35 (d.f. = 6) *p* = 0.005.I-squared (variation in SMD attributable to heterogeneity) = 67.3%.Estimate of between-study variance Tau-squared = 0.0476.Test of SMD = 0: z = 3.17 *p* = 0.002.The significance level of the combined effect quantity test: 0.05.The significance level of the heterogeneity test: 0.1.Heterogeneity test: *p* \> 0.1, no heterogeneity was considered; *p* \< 0.1, heterogeneity was considered.Fig. 3Forest figure of diastolic blood pressure

### Meta-analysis of hospital pharmaceutical care on medical cost {#Sec14}

A total of 15 studies included outcomes on patient medical costs, of which four experimental data missed sample standard deviations. Also, studies which had uneven baselines and did not report baselines were excluded. Here is the meta-analysis of the random effects model of medical cost indicators. The heterogeneity test of medical cost was significant (I^2^ = 98.3%, *p* = 0.000 \< 0.1). The test results showed that *p* = 0.078 \> 0.05, indicating that compared with usual care, hospital pharmaceutical care was not statistically significant on reducing medical cost. Therefore, it is not strong enough to support positive economic effect of this care on reducing the cost of patient care (Table [4](#Tab4){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Table 4Results of Meta-analysis of medical costStudy\| SMD\[95% Conf. Interval\]% WeightGallagher (2016) \[[@CR33]\]\|-2.2e+ 03−4.7e+ 03310.07216.28Shen (2011) \[[@CR18]\]\|-287.300−439.475− 135.12528.23Gums (1999) \[[@CR10]\]\| − 3.1e+ 03-3.4e+ 03−2.7e+ 0327.83Carter (1997) \[[@CR8]\]\|-420.000− 868.48728.48727.66D + L pooled WMD\|-1.4e+ 03−3.0e+ 03155.203100.00Heterogeneity chi-squared = 175.82 (d.f. = 3) p = 0.000.I-squared (variation in WMD attributable to heterogeneity) =98.3%.Estimate of between-study variance Tau-squared = 2.2e+ 06.Test of WMD = 0: z = 1.77 *p* = 0.078.The significance level of the combined effect quantity test: 0.05.The significance level of the heterogeneity test: 0.1.Heterogeneity test: *p* \> 0.1, no heterogeneity was considered; *p* \< 0.1, heterogeneity was considered.Fig. 4Forest figure of medical cost

### Meta-analysis of hospital pharmaceutical care on hospitalization days {#Sec15}

A total of 11 studies covered patient days of hospitalization, of which four experimental data missed sample standard deviations and four experiments had an uneven baseline. The following is the result of a meta-analysis on the random effects model of hospital stay days. The heterogeneity test of the hospitalization days was significant (I^2^ = 0.0%, *p* = 0.513 \> 0.1). The test results showed that *p* = 0.000 \< 0.05, indicating that compared with usual care, hospital pharmaceutical care could reduce hospital stay significantly, and the average length of stay between intervention group and control group was − 2.068 (95% CI, − 3.054 to − 1.082) (Table [5](#Tab5){ref-type="table"}, Fig. [5](#Fig5){ref-type="fig"}). Table 5Results of Meta-analysis of hospitalization daysStudy\| SMD\[95% Conf. Interval\]% WeightShen (2011) \[[@CR18]\]\| -1.600−2.871−0.32960.15Cies (2013) \[[@CR21]\]\| -3.000−6.1310.1319.92Dager (2014)\| -2.700−4.502−0.89829.93I-V pooled WMD\| -2.068−3.054−1.082100.00Heterogeneity chi-squared = 1.33 (d.f. = 2) p = 0.513.I-squared (variation in WMD attributable to heterogeneity) = 0.0%.Test of WMD = 0: z = 4.11 *p* = 0.000.The significance level of the combined effect quantity test: 0.05.The significance level of the heterogeneity test: 0.1.Heterogeneity test: *p* \> 0.1, no heterogeneity was considered; *p* \< 0.1, heterogeneity was considered.Fig. 5Forest figure of hospitalization days

Discussion {#Sec16}
==========

This study systematically evaluated the clinical and economic outcomes of hospital pharmaceutical and conducted a meta-analysis. This study conducted a systematic review and meta-analysis of the clinical and economic outcomes of hospital pharmaceutical care. From Table [1](#Tab1){ref-type="table"}, the vast majority of the studies showed that clinical pharmacy interventions could improve the economic and clinical outcomes, playing a significant role in improving medication errors, reducing readmission rates, and reducing medication costs. Among the 42 studies included, the primary outcomes of this service showed positive effects, among which 36 experimental groups were significantly better than their control groups, and the remaining 6 studies showed mixed or no effect.

Overall, hospital pharmaceutical care showed positive clinical outcomes. Results of the meta-analysis showed that the intervention of pharmaceutical care had a significant effect on the reduction of SBP and DBP. Meanwhile, results of the meta-analysis showed that hospital pharmaceutical care had a significant impact on hospitalization days, but no significant effect on reducing medical cost. In an academic medical intensive care unit, a randomized controlled trial was conducted on 202 patients before the intervention and 162 patients after the intervention. This study showed that the administration of medications by the pharmacist team effectively reduced inappropriate stress of ulcer prophylaxis use \[[@CR20]\], finally leading to reduced medical cost (*p* = 0.000). It might be attributed to insufficient number of relevant studies, or different calculation methods and scope for medical cost in various studies. In Carter's research, costs associated with prescriptions and visits as well as the total cost per patient were evaluated, but no specific cost items were listed. While in Gallagher's study \[[@CR34]\], medical expenses covered expenses of pharmacist, non-consultant hospital physicians, senior staff nurses, inpatient days, software costs and training costs. Although studies of Carter et al. \[[@CR9]\] and Gum \[[@CR13]\] reported positive economic effects, their sample sizes were not large enough to support its effectiveness. The small sample size was also one of the reasons for the lack of significant results.

This study has certain limitations. First, high-quality studies and total number of studies included for meta-analysis is insufficient. Researches on pharmaceutical care carried out in hospitals with strict study design are to be updated. Second, it is difficult to determine which intervention(s) of hospital pharmaceutical care caused specific effects. How much beneficial certain pharmacy services are than other pharmacy services might be the potential problem to be settled in the future.

Conclusion {#Sec17}
==========

The results of meta-analysis showed that the hospital pharmaceutical care had a significant effect on reducing SBP, DBP and hospital stay, but no significant reduction on medical cost. In addition, because the data available for meta-analyses are not sufficient, a false-negative conclusion could be easily drawn. Therefore, hospital pharmaceutical care have a positive clinical and economic elimination in terms of reducing SBP, DBP and improving patient hospital stay, but follow-ups on medical cost as well as other outcomes need more experimental data to support.

SBP

:   Systolic blood pressure

DBP

:   Diastolic blood pressure

SMD

:   Standard mean difference

WMD

:   Weighted mean difference
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